Table 3.

Cytotoxic effects of enoxacin depending on the concentration in various cancer cell lines and animal tissues.

Effect	Conc. [μM]	Cell Line/Tissue	Ref.
No cytotoxicity	31	A673	[74]
	124	Wi-38, MRC-5	[36]
	20	HEK 293	[91]
	5–100	Primary BMMs	[82]
	5–100	Raw 264.7	[77]
No genotoxicity	0–3121	WTK-1	[90]
Apoptosis	62	NCI-H460	[70]
	150	H460, A549	[69]
Apoptosis, cell cycle arrest	31–156	MCF-7	[71]
	20–80	HeLa, C33A	[73]
	124	DU145, LNCaP, VCaP, PC-3, 22Rv1, Co115	[38]
	124	HCT-116, RKO	[36]
Cytotoxicity (PI)	78–312	A375	[48]
Cytotoxicity (MTS)	31	TC 252, Patient derived ESFT spheres	[74]
Cytotoxicity (MTT)	124	HCT-116, RKO, HepG2, SNU-1, SNU-638, MDA-MB 231, MCF-7, H23, H1299, A549, MDA-MB-231, HepG2, KG1a, RAJI	[36]
	124	A673, TC252, STA-ET-8.2	[37]
	156	A375, Mel-Juso, Mel-Ho	[48]
	12.5–100	A549	[45]
Decreased invasiveness	124	DU145	[38]
Cytochrome P450 inhibition	10–1000	freshly isolated rat hepatocytes	[75]
Inhibition of osteoclastogenesis	10; 100	Primary MMO	[76]
	10–100	Primary MMO, Raw 264.7	[77]
	5; 10; 50	Primary BMMs	[82]
Inhibition of bone resorption	10; 25; 100	Primary MMO	[76]
	5; 10; 50	Primary BMMs	[82]
Inhibition of the interaction between V-ATPase B-subunit and F-actin	10; 25; 100	rabbit muscle actin and the Vma2p-MBP microfilaments	[76]
Inhibition of the interaction between microfilaments and V-ATPase (a) B2-subunit (b) a3-subunit	50	Primary MMO	[77]
Impairment of JNK signaling	25	Raw 264.7	[82]

Abbreviations: propidium iodide (PI); Ewing sarcoma family tumor (ESFT); mouse marrow osteoclasts (MMO); bone-marrow-derived macrophages (BMMs); maltose-binding protein (MBP); vacuolar H⁺-ATPase (V-ATPase).